Overview

Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

Status:
Not yet recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

This study is a prospective, multi-center, randomized, open-ended, double-arm clinical study. All eligible patients were randomly assigned to DEB-BACE combined with PD-1 inhibitor (Sindilizumab) treatment group (test group) and DEB-BACE treatment group (control group), to explore the efficacy and safety of combination therapy for stage II/III NSCLC with standard treatment failure or intolerable patients.

Phase:

N/A

Details

Lead Sponsor:

The Central Hospital of Lishui City

Collaborators:

Jiangxi Chest Hospital
Jiangxi Provincial Cancer Hospital
The First Affiliated Hospital of Zhengzhou University
Zhejiang University

Treatments:

Immune Checkpoint Inhibitors